AZD0156   Click here for help

GtoPdb Ligand ID: 9942

Synonyms: compound 64 [PMID: 29683659]
Compound class: Synthetic organic
Comment: AZD0156 is a potent and selective inhibitor of ATM serine/threonine kinase from AstraZeneca that is being developed for anti-cancer potential [1]. It potentiates the efficacy of irinotecan and olaparib in disease relevant mouse models and is currently undergoing clinical evaluation.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 74.41
Molecular weight 461.24
XLogP 2.74
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CN(CCCOc1ccc(cn1)c1ccc2c(c1)c1c(cn2)n(c(=O)n1C1CCOCC1)C)C
Isomeric SMILES CN(CCCOc1ccc(cn1)c1ccc2c(c1)c1c(cn2)n(c(=O)n1C1CCOCC1)C)C
InChI InChI=1S/C26H31N5O3/c1-29(2)11-4-12-34-24-8-6-19(16-28-24)18-5-7-22-21(15-18)25-23(17-27-22)30(3)26(32)31(25)20-9-13-33-14-10-20/h5-8,15-17,20H,4,9-14H2,1-3H3
No information available.
Summary of Clinical Use Click here for help
A Phase 1 clinical trial evaluating AZD0156 as either a monotherapy, or in combination with other chemotherapeutic agents, in patients with advanced solid tumours, is underway (see NCT02588105).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02588105 Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Phase 1 Interventional AstraZeneca